Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Combating food allergies with vaccine viruses

31.07.2013
Researchers of the Paul-Ehrlich-Institut have succeeded in preventing food allergy against chicken protein using a modified vaccine virus.

The viruses serve a dual function: They transfer genetic information of the allergen into the target cell of the immune system and they have an inherent immunomodulatory effect. The research results have been published in the online edition of the journal Allergy of 30 July 2013 (DOI 10.1111/all.12192)


Inflammation of intestinal mucosa in allergic mice (on the left; e.g. thickened basal layer) as compared to MVA-OVA-vaccinated mice with unimpaired intestinal mucosa (on the right side).
Paul-Ehrlich-Institut

Food allergies are on the increase in all industrialised countries, affecting around five per cent of all children and four per cent of all adults. Allergen avoidance is currently the only established treatment of choice. Specific immunotherapy using allergen extracts, which is common in the treatment of pollen allergies, has not yet been established for food allergies. Moreover, there is an inherent risk of serious adverse reactions including anaphylactic shock.

Researchers of the Paul-Ehrlich-Institut have therefore taken a completely novel approach towards immunotherapy of food allergy, which is based on modified vaccinia virus Ankara (MVA). MVA is a modified vaccine virus which has been found to be safe in several clinical trials in infection medicine. MVA facilitates transfer of the genetic information of the allergen to antigen presenting cells of the body. Cells infected with the virus begin to produce the allergen and present it to the immune system. Unlike the established immunotherapy of pollen or house dust mite allergy where allergen extracts are applied directly, the new method ascertains that the immune system does not come into contact with the allergen before allergen fragments are presented on the surface of antigen presenting cells. Serious allergic reactions as in the case of direct allergen uptake via food consumption can be ruled out.

Researchers in the Allergology and Virology Divisions at the Paul-Ehrlich-Institut had already been able to show that "vaccination" of mice with MVA carrying the gene for the chicken protein ovalbumin (MVA-OVA) prevented the usually considerable increase in allergy inducing IgE antibodies in response to exposure to the allergen [1].

Which clinical significance do these changes imply? To establish this, Dr Masako Toda, head of the Temporary Research Group "Experimental Allergy Models" at the PEI, and her co-workers developed a model of intestinal food allergy in mice. Sensitisation of mice to ovalbumin led to clinical symptoms such as diarrhoea, loss of bodyweight, and drop of body temperature. The researchers of the PEI were able to show that allergic symptoms could be prevented by vaccination with MVA-OVA and, what’s more, in collaboration with researchers of Tokyo University, Japan, they were able to establish that the vaccination could prevent inflammatory changes of the intestinal mucosa (see figure).

When examining the local immune response in the small intestine, the researchers were also able to prove – based on the modified release of the cytokines (inhibition of interleukin-4 and stimulation of interferon-gamma release) – that the adverse (allergic) response of TH2 helper cells was inhibited and the desired TH1 helper cell response was stimulated. ""This is the very result we wish to see in treating an allergy: the suppression of IgE and an increase in TH1 response"", Dr Stephan Scheurer explained the success of this approach. Dr Scheurer is the head of the Section "Recombinant Allergen Therapeutics" at the PEI.

The next steps to be taken by the researchers of the PEI will be to test how long this allergy protection will last and whether the therapy approach can be used to treat fully established allergies. ""If this is possible for our model allergen ovalbumin, we assume that the model can also be transferred to other food allergens"", explained Dr Scheurer.

Background

An allergy involves an excessive TH2 helper cell response. TH2 helper cells are a specialised group of lymphocytes of the immune system. During an allergic reaction, these cells respond to usually harmless antigens such as pollen, but also antigens in peanuts, hen's eggs, etc. Specific immunotherapy intends to re-establish the immune balance in favour of a TH1 helper response. In the above-described novel approach of immunotherapy, the modified virus Ankara not only serves as a transport vehicle of genetic information of the allergen but is also an effective immune modulator, since it creates a strong TH1 helper cell response against antigens. This process involves induction of allergen specific IgG2a antibodies, which can act as blocking antibodies, as well as cytokines (interferon-gamma) which counteract allergic reactions. This helps to restore a normal immune response.

Literature

[1] Albrecht M, Suezer Y, Staib C, Sutter G, Vieths S, Reese G (2008): Vaccination with a Modified Vaccinia Virus Ankara-based vaccine protects mice from allergic sensitization. J Gene Med 10: 1324-1333. Online-Abstract.

Original publication

Bohnen C, Wangorsch A, Schülke S, Nakajima-Adachi H, Hachimura S, Burggraf M, Süzer Y, Schwantes A, Sutter G, Waibler Z, Reese G, Toda M, Scheurer S, Vieths S (2013): Vaccination with recombinant modified vaccinia virus1 Ankara prevents the onset of intestinal allergy in mice.

Allergy Jul 30 [Epub ahead of print].

Weitere Informationen:

http://onlinelibrary.wiley.com/doi/10.1111/all.12192/abstract
- Publications Abstract
http://www.ncbi.nlm.nih.gov/pubmed/18816482?ordinalpos=60&itool=EntrezSystem2.
PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum
Abstract of J Gene Med-Paper
http://www.pei.de/EN/information/journalists-press/press-releases/2013/03-combating-food-allergies-with-vaccine-viruses.html

Press release on PEI-Website

Dr. Susanne Stöcker | idw
Further information:
http://www.pei.de/

More articles from Life Sciences:

nachricht Flavins keep a handy helper in their pocket
25.04.2018 | University of Freiburg

nachricht Complete skin regeneration system of fish unraveled
24.04.2018 | Tokyo Institute of Technology

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: BAM@Hannover Messe: innovative 3D printing method for space flight

At the Hannover Messe 2018, the Bundesanstalt für Materialforschung und-prüfung (BAM) will show how, in the future, astronauts could produce their own tools or spare parts in zero gravity using 3D printing. This will reduce, weight and transport costs for space missions. Visitors can experience the innovative additive manufacturing process live at the fair.

Powder-based additive manufacturing in zero gravity is the name of the project in which a component is produced by applying metallic powder layers and then...

Im Focus: Molecules Brilliantly Illuminated

Physicists at the Laboratory for Attosecond Physics, which is jointly run by Ludwig-Maximilians-Universität and the Max Planck Institute of Quantum Optics, have developed a high-power laser system that generates ultrashort pulses of light covering a large share of the mid-infrared spectrum. The researchers envisage a wide range of applications for the technology – in the early diagnosis of cancer, for instance.

Molecules are the building blocks of life. Like all other organisms, we are made of them. They control our biorhythm, and they can also reflect our state of...

Im Focus: Spider silk key to new bone-fixing composite

University of Connecticut researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

Repairing major load-bearing bones such as those in the leg can be a long and uncomfortable process.

Im Focus: Writing and deleting magnets with lasers

Study published in the journal ACS Applied Materials & Interfaces is the outcome of an international effort that included teams from Dresden and Berlin in Germany, and the US.

Scientists at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) together with colleagues from the Helmholtz-Zentrum Berlin (HZB) and the University of Virginia...

Im Focus: Gamma-ray flashes from plasma filaments

Novel highly efficient and brilliant gamma-ray source: Based on model calculations, physicists of the Max PIanck Institute for Nuclear Physics in Heidelberg propose a novel method for an efficient high-brilliance gamma-ray source. A giant collimated gamma-ray pulse is generated from the interaction of a dense ultra-relativistic electron beam with a thin solid conductor. Energetic gamma-rays are copiously produced as the electron beam splits into filaments while propagating across the conductor. The resulting gamma-ray energy and flux enable novel experiments in nuclear and fundamental physics.

The typical wavelength of light interacting with an object of the microcosm scales with the size of this object. For atoms, this ranges from visible light to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Invitation to the upcoming "Current Topics in Bioinformatics: Big Data in Genomics and Medicine"

13.04.2018 | Event News

Unique scope of UV LED technologies and applications presented in Berlin: ICULTA-2018

12.04.2018 | Event News

IWOLIA: A conference bringing together German Industrie 4.0 and French Industrie du Futur

09.04.2018 | Event News

 
Latest News

Getting electrons to move in a semiconductor

25.04.2018 | Physics and Astronomy

Reconstructing what makes us tick

25.04.2018 | Physics and Astronomy

Cheap 3-D printer can produce self-folding materials

25.04.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>